Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171738 | 0.83 | ALDH1A1 (0.44) | LMNAMAPTKDM4EALDH1A1POLB | |
| SCHEMBL169742 | 0.83 | ALDH1A1 (0.44) | LMNAKDM4EALDH1A1POLBGRM2 | |
| SCHEMBL27199458 | 0.79 | LMNA (0.59) | LMNAMAPTCYP2C9KDM4EALDH1A1 | |
| SCHEMBL171643 | 0.78 | MAPK14 (0.42) | ALDH1A1GRM2 | |
| SCHEMBL27199572 | 0.77 | LMNA (0.64) | LMNAMAPTCYP2C9KDM4EALDH1A1 | |
| SCHEMBL4376100 | 0.75 | MAPK14 (0.69) | LMNAMAPTCYP2C9KDM4EALDH1A1 | |
| SCHEMBL16312705 | 0.74 | GRM2 (0.47) | LMNAMAPTHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL10460796 | 0.73 | LMNA (0.62) | LMNAMAPTCYP2C9KDM4EALDH1A1 | |
| SCHEMBL4682507 | 0.72 | GRM2 (0.46) | LMNAMAPTHCRTR1HCRTR2CYP3A4 | |
| SCHEMBL5439922 | 0.71 | ALDH1A1 (0.73) | LMNAMAPTKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266834-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266834-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | JANSSEN PHARMACEUTICALS INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | JANSSEN PHARMACEUTICALS INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8841323-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841323-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2426125-A1 | 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | GRM2, GRM1, GRM3 | LMNA 3852/4885MAPT 2624/4885CYP2C9 1553/4885 |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | LMNA 3831/4885MAPT 2635/4885CYP2C9 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.